
Circe Biosciences
Developing a manufacturing platform capable of producing any organic molecule using carbon dioxide, water, and electricity.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor investor investor | €0.0 | round | |
$5.0m Valuation: $40.0m | Seed | ||
Total Funding | 000k |
Related Content
Circe Biosciences, Inc. operates at the intersection of synthetic biology and decarbonization, developing a manufacturing platform that transforms carbon dioxide into a variety of valuable chemicals. The company was co-founded by Shannon Nangle and Marika Ziesack, who both bring extensive experience from the Wyss Institute for Biologically Inspired Engineering at Harvard University. Their collective background in gas fermentation and synthetic biology underpins the company's core technology. The process leverages gas fermentation, utilizing microbes that consume greenhouse gases like carbon dioxide, along with water and electricity, to produce a range of organic molecules.
The primary goal is to provide a sustainable alternative to traditional petrochemical-based manufacturing, thereby reducing the carbon footprint of numerous industries. Circe Biosciences' platform is designed to create products such as triglycerides for food production, bioplastics, and other specialty chemicals. This approach targets industries reliant on these materials, offering them a method to decarbonize their supply chains. The business model appears to be centered on producing and selling these sustainably sourced molecules or potentially licensing the technology to large-scale manufacturing partners. By converting a waste product (CO2) into essential goods, the company aims to build a more resilient and circular economy.
The company's platform functions by engineering microbes to be highly efficient at converting CO2 into specific target molecules. This fermentation process is positioned as a direct competitor to conventional methods that rely on fossil fuels. Significant milestones include securing a $1 million investment from The Engine, a venture firm with roots at MIT, which has provided crucial early-stage support. The company has also been recognized through various awards, including participation in the 2022 cohort of the Third Derivative accelerator program, underscoring its potential impact on climate technology. This technology offers the benefit of producing familiar products through a fundamentally different and more environmentally friendly pathway.
Keywords: gas fermentation, carbon capture, synthetic biology, decarbonization, sustainable manufacturing, alternative proteins, biochemicals, climate tech, circular economy, industrial biotechnology